<!DOCTYPE html><html><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Roboto+Slab:wght@100..900&family=Roboto:ital,wght@0,100;0,300;0,400;0,500;0,700;0,900;1,100;1,300;1,400;1,500;1,700;1,900&display=swap" rel="stylesheet">
    <style type="text/css">
      @media (prefers-color-scheme: light) {body {color: #1a1b21;}}
      @media (prefers-color-scheme: dark) {body {color: white;}}
      body {margin-left: 1rem; margin-right: 1rem; font-family: Roboto, sans-serif;}
      h2 {font-size: 1.2rem;}
      h3 {font-size: 1.1rem;}
      h4 {font-size: 1rem;}
      p, ul, ol {font-size: .9rem;line-height: 1.5rem; letter-spacing: .05rem;}
    </style>
</head>
<body>
<p>Below are general guidelines for Extracorporeal Life Support (ECLS/ECMO) used at the MGH for adult medical patients. Final decisions regarding an individual patient's inclusion/exclusion should be made by ECLS certified faculty using appropriate clinical judgment. We encourage calls to MGH to discuss individual cases.</p>
<ul>
  <li>Usual medical and surgical treatments have failed, and the patient is at high risk of death without mechanical circulatory support including patients who are unable to separate from cardiopulmonary bypass.</li>
  <li>The patient must have a reasonable expectation of myocardial/pulmonary recovery with time OR be a candidate for consideration of a durable mechanical circulatory support device and/or transplantation.</li>
  <li>The patient should not have suffered catastrophic neurologic damage. Neurologic status should be assessed via clinical exam or imaging whenever possible.</li>
</ul>
<hr/>
<h2>Indications for VA ECMO:</h2>
<ul>
  <li>Inadequate tissue perfusion and shock manifesting as hypotension and low cardiac output despite volume administration, inotropes and vasopressors, and standard therapies</li>
</ul>
<hr/>
<h2>Indications for VV ECMO:</h2>
<ul>
    <li>Acute respiratory failure of all causes when the risk of mortality is high as identified by a PaO2/FiO2 < 150 on FiO2 > 90%</li>
    <li>Uncompensated CO2 retention PaCO2 > 60, and pH < 7.25 with inability to mechanically ventilate</li>
    <li>Inability to achieve safe inflation pressures (Driving P ≤ 15 cm H2O or Pplat ≤ 30 cm HO)</li>
</ul>
<hr/>
<h2>Common indications:</h2>
<ul>
  <li>Cardiogenic shock: all causes</li>
  <li>Refractory VT / VF</li>
  <li>Cardiac arrest without ROSC</li>
  <li>Early failure post heart or lung transplant</li>
  <li>Pulmonary embolism</li>
  <li>Acute anaphylaxis</li>
  <li>Sepsis with profound cardiac depression</li>
  <li>Bridge to cardiac transplant / mech support</li>
  <li>Post cardiac surgery failure (unable to wean from CPB)</li>
</ul>
<hr/>
<h2>Common indications:</h2>
<ul>
  <li>Severe pneumonia or aspiration</li>
  <li>ARDS</li>
  <li>Acute lung failure (PGD) post transplant</li>
  <li>Pulmonary contusion</li>
  <li>Bridge to lung transplant</li>
  <li>Toxic inhalation</li>
  <li>Status asthmaticus</li>
  <li>Airway obstruction, i.e. mediastinal masses • Severe air leak syndrome</li>
</ul>
<hr/>
<h2>Absolute Contraindications to All Forms of ECMO:</h2>
<ul>
  <li>Non-recoverable multi-organ failure or neurologic disease</li>
  <li>Unwitnessed cardiac arrest or CPR > 30 min without ROSC</li>
  <li>Active severe bleeding</li>
  <li>Contraindication to anticoagulation or refusal to receive blood products</li>
  <li>Recent neurosurgical procedures or intracranial bleeding (within 10 days)</li>
  <li>End stage liver disease or renal disease on dialysis Absolute Contraindications to VA ECMO:</li>
  <li>Acute Aortic dissection</li>
  <li>Severe aortic valve regurgitation</li>
</ul>
<h2>Relative Contraindications to ECMO:</h2>
<ul>
  <li>Age > 70 years</li>
</ul>
<h2>Absolute Contraindications to VV ECMO:</h2>
<ul>
  <li>Severe right or left heart failure (Consider VA ECMO)</li>
  <li>BMI > 40</li>
  <li>Unknown neurologic status</li>
  <li>Multiple organ failure</li>
  <li>Prolonged mechanical ventilation</li>
  <li>Severe pulmonary hypertension in a non-transplant candidate</li>
  <li>Active malignancy, graft vs. host disease or significant immunosuppression</li>
</ul>
<hr/>
<h2>Typical Patient Profiles:</h2>
<h3>Veno-Arterial ECMO (Circulatory Support)</h3>
<h4>Cardiogenic Shock</h4>
<ol>
  <li>Cl < 2.2 L/min/m2 or SVO2 < 60% (on two inotro- pes)</li>
  <li>High biventricular filling pressures: PCW > 20, CVP > 15</li>
  <li>Rising lactate</li>
  <li>Worsening metabolic acidosis</li>
  <li>Hypotension with significant vasopressor require- ment (two or more of the following):
    <ul>
      <li>Norepinephrine ≥ 50 mcg/min - Vasopressin ≥ 0.04 units/min</li>
      <li>Phenylephrine ≥ 100 mcg/min - Epinephrine ≥ 5 mcg/min </li>
    </ul>
  </li>
</ol>
<p><strong>Unstable arrhythmias</strong></p>
<h3>Veno-venous ECMO (Lung Support)</h3>
<h4>Acute Respiratory Failure</h4>
<ol>
  <li>Sat ≤ 88% on FiO2 100% and PEEP ≥ 15, with plateau pressure ≥ 30cmH2O</li>
  <li>pH < 7.20</li>
  <li>FiO2 > 70% for Lung Transplant patient</li>
  <li>Normal RV/LV function</li>
  <li>Minimal vasopressor/inotrope requirements</li>
  <li>Paralysis, Inhaled Nitric Oxide or Epoprostenol and /or prone positioning attempted</li>
</ol>
<br/><br/><br/><br/><br/>
</body>
</html>